Gables Capital Management’s Lexaria Bioscience LEXX Stock Holding History

Gables Capital Management’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10	Hold	13	–	–	﹤0.01%	471
2025 Q4	$8	Hold	13	–	–	﹤0.01%	463
2025 Q3	$12	Hold	13	–	–	﹤0.01%	457
2025 Q2	$11	Hold	13	–	–	﹤0.01%	442
2025 Q1	$22	Hold	13	–	–	﹤0.01%	442
2024 Q4	$27	Hold	13	–	–	﹤0.01%	443
2024 Q3	$40	Hold	13	–	–	﹤0.01%	443
2024 Q2	$36	Hold	13	–	–	﹤0.01%	394
2024 Q1	$47	Hold	13	–	–	﹤0.01%	388
2023 Q4	$16	Hold	13	–	–	﹤0.01%	377
2023 Q3	$13	Buy	+13	New	+$12	﹤0.01%	363
2023 Q2	–	Sell	-13	Closed	-$35	–	379
2023 Q1	$35	Hold	13	–	–	﹤0.01%	374
2022 Q4	$32	Hold	13	–	–	﹤0.01%	358
2022 Q3	$0	Hold	13	–	–	﹤0.01%	346
2022 Q2	$0	Hold	13	–	–	﹤0.01%	354
2022 Q1	$0	Hold	13	–	–	﹤0.01%	349
2021 Q4	$0	Hold	13	–	–	﹤0.01%	354
2021 Q3	$0	Buy	+13	New	+$83	﹤0.01%	358

Other funds holding LEXX

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Gables Capital Management's LEXX Position: Q1 2026 in Review

Gables Capital Management held its Lexaria Bioscience (LEXX) position steady in Q1 2026 at 13 shares worth $10. The position accounts for ﹤0.01% of the portfolio, ranked #471.

Gables Capital Management first reported a position in LEXX in Q3 2021 and has held it in 18 quarters since. The position peaked at $47 in Q1 2024. 28 funds tracked by Wall St. Rank hold LEXX as of Q1 2026.

Gables Capital Management held 13 shares of Lexaria Bioscience worth $10 as of Q1 2026.
Gables Capital Management left its Lexaria Bioscience share count unchanged in Q1 2026.
Lexaria Bioscience made up ﹤0.01% of Gables Capital Management's portfolio in Q1 2026, its #471 holding.
Gables Capital Management first reported a position in Lexaria Bioscience in Q3 2021 and has held it in 18 quarters since.
Gables Capital Management's Lexaria Bioscience position peaked at $47 in Q1 2024.
28 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q1 2026.

Based on Gables Capital Management's 13F filing for Q1 2026, filed 1 May 2026.